Victrex plc with ticker (LON:VCT) now has a potential upside of 31.1% according to JP Morgan.
JP Morgan set a target price of 1,750 GBX for the company, which when compared to the Victrex plc share price of 1,335 GBX at opening today (26/06/2023) indicates a potential upside of 31.1%. Trading has ranged between 1,320 (52 week low) and 1,953 (52 week high) with an average of 201,321 shares exchanging hands daily. The market capitalisation at the time of writing is £1,177,358,681.
Victrex plc is a United Kingdom-based holding company. The principal activity of the Company is the manufacturing and selling of high-performance polymers. The Company develops polyetheretherketone (PEEK) and PAEK polymer solutions, and semi-finished and finished parts. The Company operates through two segments: Industrial and Medical. Industrial segment is focuses on its energy and industrial, value-added resellers (VAR), automotive, aerospace, and electronics markets. Medical segment is focuses on providing specialist solutions for medical device manufacturers. The Company’s subsidiaries include Victrex Manufacturing Limited, Invibio Limited, Invibio Knees Limited, Invibio Device Component Manufacturing Limited and Juvora Limited.
Victrex plc 31.1% potential upside indicated by JP Morgan
[shareaholic app="share_buttons" id_name="post_below_content"]
- Written by: Charlotte Edwards
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Victrex plc (LON:VCT) announces interim results for the 6 months ended 31 March 2024, highlighting revenue, profit, and growth targets. CEO Jakob Sigurdsson provides insights.
Victrex plc is a world leader in high-performance polymer solutions. In their Q1 2024 statement, they report a decline in revenue and volume but highlight progress in certain end-markets. They also discuss their financial position and cost actions. CEO Jakob Sigurdsson remains optimistic about the opportunity for progress in the future.
